;PMID: 9431830
;source_file_631.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..149] = [t:49..149]
;2)section:[e:153..188] = [t:153..188]
;3)section:[e:192..310] = [t:192..310]
;4)sentence:[e:314..319] = [t:314..319]
;5)sentence:[e:320..523] = [t:320..523]
;6)sentence:[e:524..532] = [t:524..532]
;7)sentence:[e:533..888] = [t:533..888]
;8)sentence:[e:889..897] = [t:889..897]
;9)sentence:[e:898..982] = [t:898..982]
;10)sentence:[e:983..1115] = [t:983..1115]
;11)sentence:[e:1116..1227] = [t:1116..1227]
;12)sentence:[e:1228..1302] = [t:1228..1302]
;13)sentence:[e:1303..1542] = [t:1303..1542]
;14)sentence:[e:1543..1651] = [t:1543..1651]
;15)sentence:[e:1652..1784] = [t:1652..1784]
;16)sentence:[e:1785..1977] = [t:1785..1977]
;17)sentence:[e:1978..1990] = [t:1978..1990]
;18)sentence:[e:1991..2161] = [t:1991..2161]
;19)section:[e:2165..2209] = [t:2165..2209]
;Token/POS Errors
;ERROR_POS mismatch [33..34] t:token e:CD 6

;section 0 Span:0..43
;Br J Clin Pharmacol. 1997 Dec;44(6):549-55.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..9] Clin)
        (NNP:[10..19] Pharmacol) (.:[19..20] .) (CD:[21..25] 1997)
        (NNPS:[26..32] Dec;44) (CC:[32..33] -LRB-) (token:[33..34] 6)
        (NN:[34..35] -RRB-) (::[35..36] :) (CD:[36..38] 54) (CD:[38..42] 9-55)
        (.:[42..43] .)))

;sentence 1 Span:49..149
;Characterization of the human cytochrome P450 enzymes involved in the
;metabolism  of dihydrocodeine.
;[79..102]:cyp450:"cytochrome P450 enzymes"
;[134..148]:substance:"dihydrocodeine"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[49..65] Characterization))
      (PP (IN:[66..68] of)
        (NP (DT:[69..72] the)
          (NML (JJ:[73..78] human) (NN:[79..89] cytochrome) (NN:[90..94] P450))
          (NNS:[95..102] enzymes))))
    (VP (JJ:[103..111] involved)
      (NP (-NONE-:[111..111] *))
      (PP-CLR (IN:[112..114] in)
        (NP
          (NP (DT:[115..118] the) (NN:[119..129] metabolism))
          (PP (IN:[131..133] of)
            (NP (NN:[134..148] dihydrocodeine))))))
    (.:[148..149] .)))

;section 2 Span:153..188
;Kirkwood LC, Nation RL, Somogyi AA.
(SEC
  (FRAG (NNP:[153..161] Kirkwood) (NNP:[162..164] LC) (,:[164..165] ,)
        (NNP:[166..172] Nation) (NNP:[173..175] RL) (,:[175..176] ,)
        (NNP:[177..184] Somogyi) (NNP:[185..187] AA) (.:[187..188] .)))

;section 3 Span:192..310
;Centre for Pharmaceutical Research, School of Pharmacy and Medical Sciences, 
;University of South Australia, Adelaide.
(SEC
  (FRAG (NNP:[192..198] Centre) (NNP:[199..202] for)
        (NNP:[203..217] Pharmaceutical) (NNP:[218..226] Research)
        (NNP:[226..227] ,) (NNP:[228..234] School) (IN:[235..237] of)
        (NNP:[238..246] Pharmacy) (CC:[247..250] and) (NNP:[251..258] Medical)
        (NNP:[259..267] Sciences) (,:[267..268] ,) (NNP:[270..280] University)
        (IN:[281..283] of) (NNP:[284..289] South) (NNP:[290..299] Australia)
        (,:[299..300] ,) (NNP:[301..309] Adelaide) (.:[309..310] .)))

;sentence 4 Span:314..319
;AIMS:
(SENT
  (NP (NNS:[314..318] AIMS) (::[318..319] :)))

;sentence 5 Span:320..523
;Using human liver microsomes from donors of the CYP2D6 poor and extensive 
;metabolizer genotypes, the role of individual cytochromes P-450 in the
;oxidative  metabolism of dihydrocodeine was investigated.
;[368..374]:cyp450:"CYP2D6"
;[441..458]:cyp450:"cytochromes P-450"
;[491..505]:substance:"dihydrocodeine"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[320..320] *))
      (VP (VBG:[320..325] Using)
        (NP
          (NP (JJ:[326..331] human) (NN:[332..337] liver)
              (NNS:[338..348] microsomes))
          (PP (IN:[349..353] from)
            (NP
              (NP (NNS:[354..360] donors))
              (PP (IN:[361..363] of)
                (NP (DT:[364..367] the)
                  (NP
                    (NML
                      (ADJP
                        (NML-2 (NN:[368..374] CYP2D6))
                        (JJ:[375..379] poor))
                      (NML-3 (-NONE-:[379..379] *P*)))
                    (CC:[380..383] and)
                    (NML
                      (ADJP
                        (NML-2 (-NONE-:[383..383] *P*))
                        (JJ:[384..393] extensive))
                      (NML-3 (NN:[395..406] metabolizer)
                             (NNS:[407..416] genotypes)))))))))))
    (,:[416..417] ,)
    (NP-SBJ-1
      (NP
        (NP (DT:[418..421] the) (NN:[422..426] role))
        (PP (IN:[427..429] of)
          (NP (JJ:[430..440] individual)
             (NNS:[441..452] cytochromes) (NN:[453..458] P-450))))
      (PP (IN:[459..461] in)
        (NP
          (NP (DT:[462..465] the) (JJ:[466..475] oxidative)
              (NN:[477..487] metabolism))
          (PP (IN:[488..490] of)
            (NP (NN:[491..505] dihydrocodeine))))))
    (VP (VBD:[506..509] was)
      (VP (VBN:[510..522] investigated)
        (NP-1 (-NONE-:[522..522] *))))
    (.:[522..523] .)))

;sentence 6 Span:524..532
;METHODS:
(SENT
  (NP (NNS:[524..531] METHODS) (::[531..532] :)))

;sentence 7 Span:533..888
;The kinetics of  formation of N- and O-demethylated metabolites,
;nordihydrocodeine and  dihydromorphine, were determined using microsomes from
;six extensive and one  poor metabolizer and the effects of chemical
;inhibitors selective for individual  P-450 enzymes of the 1A, 2A, 2C, 2D, 2E
;and 3A families and of LKM1  (anti-CYP2D6) antibodies were studied.
;[585..596]:substance:"metabolites"
;[598..615]:substance:"nordihydrocodeine"
;[621..636]:substance:"dihydromorphine"
;[735..754]:substance:"chemical inhibitors"
;[781..794]:cyp450:"P-450 enzymes"
;[802..804]...[828..836]:cyp450:"1A"..."families"
;[806..808]...[828..836]:cyp450:"2A"..."families"
;[810..813]...[828..836]:cyp450:"2C,"..."families"
;[814..816]...[828..836]:cyp450:"2D"..."families"
;[818..820]...[828..836]:cyp450:"2E"..."families"
;[825..836]:cyp450:"3A families"
;[844..874]:substance:"LKM1  (anti-CYP2D6) antibodies"
(SENT
  (S
    (S
      (NP-SBJ-3
        (NP (DT:[533..536] The) (NNS:[537..545] kinetics))
        (PP (IN:[546..548] of)
          (NP
            (NP (NN:[550..559] formation))
            (PP (IN:[560..562] of)
              (NP
                (NP
                  (NP
                    (ADJP (NN:[563..564] N) (HYPH:[564..565] -)
                      (ADJP-4 (-NONE-:[565..565] *P*)))
                    (NML-6 (-NONE-:[565..565] *P*)))
                  (CC:[566..569] and)
                  (NP
                    (ADJP (NN:[570..571] O) (HYPH:[571..572] -)
                      (ADJP-4 (VBN:[572..584] demethylated)))
                    (NML-6 (NNS:[585..596] metabolites))))
                (,:[596..597] ,)
                (NP (NN:[598..615] nordihydrocodeine) (CC:[616..619] and)
                    (NN:[621..636] dihydromorphine)))))))
      (,:[636..637] ,)
      (VP (VBD:[638..642] were)
        (VP (VBN:[643..653] determined)
          (NP-3 (-NONE-:[653..653] *))
          (S-MNR
            (NP-SBJ (-NONE-:[653..653] *))
            (VP (VBG:[654..659] using)
              (NP
                (NP (NNS:[660..670] microsomes))
                (PP (IN:[671..675] from)
                  (NP
                    (NP (CD:[676..679] six) (JJ:[680..689] extensive)
                      (NML-2 (-NONE-:[689..689] *P*)))
                    (CC:[690..693] and)
                    (NP (CD:[694..697] one) (JJ:[699..703] poor)
                      (NML-2 (NN:[704..715] metabolizer)))))))))))
    (CC:[716..719] and)
    (S
      (NP-SBJ-1
        (NP (DT:[720..723] the) (NNS:[724..731] effects))
        (PP (IN:[732..734] of)
          (NP
            (NP (JJ:[735..743] chemical) (NNS:[744..754] inhibitors))
            (ADJP (JJ:[755..764] selective)
              (PP (IN:[765..768] for)
                (NP
                  (NP (JJ:[769..779] individual)
                     (NN:[781..786] P-450) (NN:[787..794] enzymes))
                  (PP
                    (PP (IN:[795..797] of)
                      (NP (DT:[798..801] the)
                        (NML
                          (NML (NN:[802..804] 1A)
                            (NML-5 (-NONE-:[804..804] *P*)))
                          (,:[804..805] ,)
                          (NML (NN:[806..808] 2A)
                            (NML-5 (-NONE-:[808..808] *P*)))
                          (,:[808..809] ,)
                          (NML (NN:[810..812] 2C)
                            (NML-5 (-NONE-:[812..812] *P*)))
                          (,:[812..813] ,)
                          (NML (NN:[814..816] 2D)
                            (NML-5 (-NONE-:[816..816] *P*)))
                          (,:[816..817] ,)
                          (NML (NN:[818..820] 2E)
                            (NML-5 (-NONE-:[820..820] *P*)))
                          (CC:[821..824] and)
                          (NML (NN:[825..827] 3A)
                            (NML-5 (NNS:[828..836] families))))))
                    (CC:[837..840] and)
                    (PP (IN:[841..843] of)
                      (NP
                        (NML (NN:[844..848] LKM1)
                          (NP (-LRB-:[850..851] -LRB-) (AFX:[851..855] anti)
                              (HYPH:[855..856] -) (NN:[856..862] CYP2D6)
                              (-RRB-:[862..863] -RRB-)))
                        (NNS:[864..874] antibodies))))))))))
      (VP (VBD:[875..879] were)
        (VP (VBN:[880..887] studied)
          (NP-1 (-NONE-:[887..887] *)))))
    (.:[887..888] .)))

;sentence 8 Span:889..897
;RESULTS:
(SENT
  (NP (NNS:[889..896] RESULTS) (::[896..897] :)))

;sentence 9 Span:898..982
;Nordihydrocodeine was the major  metabolite in both poor and extensive
;metabolizers.
;[898..915]:substance:"Nordihydrocodeine"
;[931..941]:substance:"metabolite"
(SENT
  (S
    (NP-SBJ (NN:[898..915] Nordihydrocodeine))
    (VP (VBD:[916..919] was)
      (NP-PRD (DT:[920..923] the) (JJ:[924..929] major)
              (NN:[931..941] metabolite))
      (PP-LOC (IN:[942..944] in)
        (NP (CC:[945..949] both)
          (NML
            (NML (JJ:[950..954] poor)
              (NML-1 (-NONE-:[954..954] *P*)))
            (CC:[955..958] and)
            (NML (JJ:[959..968] extensive)
              (NML-1 (NNS:[969..981] metabolizers)))))))
    (.:[981..982] .)))

;sentence 10 Span:983..1115
;Kinetic constants for  N-demethylation derived from the single enzyme
;Michaelis-Menten model did not  differ between the two groups.
;[1046..1052]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[983..990] Kinetic) (NNS:[991..1000] constants))
        (PP (IN:[1001..1004] for)
          (NP (NN:[1006..1021] N-demethylation))))
      (VP (VBN:[1022..1029] derived)
        (NP (-NONE-:[1029..1029] *))
        (PP (IN:[1030..1034] from)
          (NP (DT:[1035..1038] the)
            (NML (JJ:[1039..1045] single) (NN:[1046..1052] enzyme))
            (NML (NNP:[1053..1062] Michaelis) (HYPH:[1062..1063] -)
                 (NNP:[1063..1069] Menten))
            (NN:[1070..1075] model)))))
    (VP (VBD:[1076..1079] did) (RB:[1080..1083] not)
      (VP (VB:[1085..1091] differ)
        (PP (IN:[1092..1099] between)
          (NP (DT:[1100..1103] the) (CD:[1104..1107] two)
              (NNS:[1108..1114] groups)))))
    (.:[1114..1115] .)))

;sentence 11 Span:1116..1227
;Troleandomycin and erythromycin selectively  inhibited N-demethylation in
;both extensive and poor metabolizers.
;[1116..1130]:substance:"Troleandomycin"
;[1135..1147]:substance:"erythromycin"
(SENT
  (S
    (NP-SBJ (NN:[1116..1130] Troleandomycin) (CC:[1131..1134] and)
            (NN:[1135..1147] erythromycin))
    (ADVP (RB:[1148..1159] selectively))
    (VP (VBD:[1161..1170] inhibited)
      (NP (NN:[1171..1186] N-demethylation))
      (PP-LOC (IN:[1187..1189] in)
        (NP (CC:[1190..1194] both)
          (NP (JJ:[1195..1204] extensive)
            (NML-1 (-NONE-:[1204..1204] *P*)))
          (CC:[1205..1208] and)
          (NP (JJ:[1209..1213] poor)
            (NML-1 (NNS:[1214..1226] metabolizers))))))
    (.:[1226..1227] .)))

;sentence 12 Span:1228..1302
;The CYP3A  inducer, alpha-naphthoflavone, increased N-demethylation rates.
;[1232..1237]:cyp450:"CYP3A"
;[1239..1246]:substance:"inducer"
;[1248..1268]:substance:"alpha-naphthoflavone"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1228..1231] The) (NN:[1232..1237] CYP3A)
          (NN:[1239..1246] inducer))
      (,:[1246..1247] ,)
      (NP (NN:[1248..1268] alpha-naphthoflavone)))
    (,:[1268..1269] ,)
    (VP (VBD:[1270..1279] increased)
      (NP (NN:[1280..1295] N-demethylation) (NNS:[1296..1301] rates)))
    (.:[1301..1302] .)))

;sentence 13 Span:1303..1542
;The kinetics of  formation of dihydromorphine in both groups were best
;described by a single  enzyme Michaelis-Menten model although inhibition
;studies in extensive  metabolizers suggested involvement of two enzymes with
;similar Km values.
;[1333..1348]:substance:"dihydromorphine"
;[1397..1403]:substance:"enzyme"
;[1511..1518]:substance:"enzymes"
;[1532..1534]:quantitative-name:"Km"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1303..1306] The) (NNS:[1307..1315] kinetics))
      (PP (IN:[1316..1318] of)
        (NP
          (NP (NN:[1320..1329] formation))
          (PP (IN:[1330..1332] of)
            (NP (NN:[1333..1348] dihydromorphine)))))
      (PP-LOC (IN:[1349..1351] in)
        (NP (DT:[1352..1356] both) (NNS:[1357..1363] groups))))
    (VP (VBD:[1364..1368] were)
      (ADVP (RBS:[1369..1373] best))
      (VP (VBN:[1374..1383] described)
        (NP-1 (-NONE-:[1383..1383] *))
        (PP (IN:[1384..1386] by)
          (NP-LGS (DT:[1387..1388] a)
            (NML (JJ:[1389..1395] single) (NN:[1397..1403] enzyme))
            (NML (NNP:[1404..1413] Michaelis) (HYPH:[1413..1414] -)
                 (NNP:[1414..1420] Menten))
            (NN:[1421..1426] model)))))
    (SBAR-ADV (IN:[1427..1435] although)
      (S
        (NP-SBJ
          (NP (NN:[1436..1446] inhibition) (NNS:[1447..1454] studies))
          (PP (IN:[1455..1457] in)
            (NP (JJ:[1458..1467] extensive) (NNS:[1469..1481] metabolizers))))
        (VP (VBD:[1482..1491] suggested)
          (NP
            (NP (NN:[1492..1503] involvement))
            (PP (IN:[1504..1506] of)
              (NP
                (NP (CD:[1507..1510] two) (NNS:[1511..1518] enzymes))
                (PP (IN:[1519..1523] with)
                  (NP (JJ:[1524..1531] similar) (NN:[1532..1534] Km)
                      (NNS:[1535..1541] values)))))))))
    (.:[1541..1542] .)))

;sentence 14 Span:1543..1651
;The  kinetic constants for O-demethylation were significantly different in
;extensive  and poor metabolizers.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1543..1546] The) (JJ:[1548..1555] kinetic)
          (NNS:[1556..1565] constants))
      (PP (IN:[1566..1569] for)
        (NP (NN:[1570..1585] O-demethylation))))
    (VP (VBD:[1586..1590] were)
      (ADJP-PRD
        (ADVP (RB:[1591..1604] significantly))
        (JJ:[1605..1614] different)
        (PP-LOC (IN:[1615..1617] in)
          (NP
            (NP (JJ:[1618..1627] extensive)
              (NML-1 (-NONE-:[1627..1627] *P*)))
            (CC:[1629..1632] and)
            (NP (JJ:[1633..1637] poor)
              (NML-1 (NNS:[1638..1650] metabolizers)))))))
    (.:[1650..1651] .)))

;sentence 15 Span:1652..1784
;The extensive metabolizers had a mean intrinsic clearance  to dihydromorphine
;more than ten times greater than the poor metabolizer.
;[1714..1729]:substance:"dihydromorphine"
;[1730..1749]:quantitative-value:"more than ten times"
(SENT
  (S
    (NP-SBJ (DT:[1652..1655] The) (JJ:[1656..1665] extensive)
            (NNS:[1666..1678] metabolizers))
    (VP (VBD:[1679..1682] had)
      (NP
        (NP
          (NP (DT:[1683..1684] a) (JJ:[1685..1689] mean)
              (JJ:[1690..1699] intrinsic) (NN:[1700..1709] clearance))
          (PP (TO:[1711..1713] to)
            (NP (NN:[1714..1729] dihydromorphine))))
        (ADJP
          (ADJP
            (NML
              (QP (RBR:[1730..1734] more) (IN:[1735..1739] than)
                  (CD:[1740..1743] ten) (NNS:[1744..1749] times)))
            (JJR:[1750..1757] greater))
          (PP (IN:[1758..1762] than)
            (NP (DT:[1763..1766] the) (JJ:[1767..1771] poor)
                (NN:[1772..1783] metabolizer))))))
    (.:[1783..1784] .)))

;sentence 16 Span:1785..1977
;The  CYP2D6 chemical inhibitors, quinidine and quinine, and LKM1 antibodies
;inhibited  O-demethylation in extensive metabolizers; no effect was observed
;in microsomes  from a poor metabolizer.
;[1790..1796]:cyp450:"CYP2D6"
;[1797..1816]:substance:"chemical inhibitors"
;[1818..1827]:substance:"quinidine"
;[1832..1839]:substance:"quinine"
;[1845..1860]:substance:"LKM1 antibodies"
(SENT
  (S
    (S
      (NP-SBJ
        (NP
          (NP (DT:[1785..1788] The) (NN:[1790..1796] CYP2D6)
             (JJ:[1797..1805] chemical) (NNS:[1806..1816] inhibitors))
          (,:[1816..1817] ,)
          (NP (NN:[1818..1827] quinidine) (CC:[1828..1831] and)
              (NN:[1832..1839] quinine)))
        (,:[1839..1840] ,) (CC:[1841..1844] and)
        (NP (NN:[1845..1849] LKM1) (NNS:[1850..1860] antibodies)))
      (VP (VBD:[1861..1870] inhibited)
        (NP (NN:[1872..1887] O-demethylation))
        (PP (IN:[1888..1890] in)
          (NP (JJ:[1891..1900] extensive) (NNS:[1901..1913] metabolizers)))))
    (::[1913..1914] ;)
    (S
      (NP-SBJ-1 (DT:[1915..1917] no) (NN:[1918..1924] effect))
      (VP (VBD:[1925..1928] was)
        (VP (VBN:[1929..1937] observed)
          (NP-1 (-NONE-:[1937..1937] *))
          (PP-LOC (IN:[1938..1940] in)
            (NP
              (NP (NNS:[1941..1951] microsomes))
              (PP (IN:[1953..1957] from)
                (NP (DT:[1958..1959] a) (JJ:[1960..1964] poor)
                    (NN:[1965..1976] metabolizer))))))))
    (.:[1976..1977] .)))

;sentence 17 Span:1978..1990
;CONCLUSIONS:
(SENT
  (NP (NNS:[1978..1989] CONCLUSIONS) (::[1989..1990] :)))

;sentence 18 Span:1991..2161
;CYP2D6 is the major enzyme mediating  O-demethylation of dihydrocodeine to
;dihydromorphine. In contrast,  nordihydrocodeine formation is predominantly
;catalysed by CYP3A.
;[1991..1997]:cyp450:"CYP2D6"
;[2011..2017]:cyp450:"enzyme"
;[2048..2062]:substance:"dihydrocodeine"
;[2066..2081]:substance:"dihydromorphine"
;[2097..2114]:substance:"nordihydrocodeine"
;[2155..2160]:cyp450:"CYP3A"
(SENT
  (S
    (NP-SBJ (NN:[1991..1997] CYP2D6))
    (VP (VBZ:[1998..2000] is)
      (NP-PRD
        (NP (DT:[2001..2004] the) (JJ:[2005..2010] major)
            (NN:[2011..2017] enzyme))
        (VP (VBG:[2018..2027] mediating)
          (NP
            (NP (NN:[2029..2044] O-demethylation))
            (PP (IN:[2045..2047] of)
              (NP (NN:[2048..2062] dihydrocodeine)))
            (PP (TO:[2063..2065] to)
              (NP (NN:[2066..2081] dihydromorphine)))))))
    (.:[2081..2082] .))
  (S
    (PP (IN:[2083..2085] In)
      (NP (NN:[2086..2094] contrast)))
    (,:[2094..2095] ,)
    (NP-SBJ-1 (NN:[2097..2114] nordihydrocodeine) (NN:[2115..2124] formation))
    (VP (VBZ:[2125..2127] is)
      (VP
        (ADVP (RB:[2128..2141] predominantly))
        (VBN:[2142..2151] catalysed)
        (NP-1 (-NONE-:[2151..2151] *))
        (PP (IN:[2152..2154] by)
          (NP-LGS (NN:[2155..2160] CYP3A)))))
    (.:[2160..2161] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1991..2161]::S:S:

;section 19 Span:2165..2209
;PMID: 9431830 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2165..2169] PMID) (::[2169..2170] :) (CD:[2171..2178] 9431830)
        (NN:[2179..2180] -LSB-) (NNP:[2180..2186] PubMed) (::[2187..2188] -)
        (NN:[2189..2196] indexed) (IN:[2197..2200] for)
        (NNP:[2201..2209] MEDLINE-RSB-)))
